Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Investigation of Diacylglycerol Lipase Alpha Inhibition in the Mouse Lipopolysaccharide Inflammatory Pain Model.

Wilkerson JL, Donvito G, Grim TW, Abdullah RA, Ogasawara D, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2017 Dec;363(3):394-401. doi: 10.1124/jpet.117.243808. Epub 2017 Oct 2.


Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.

Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2017 Jul;362(1):210-218. doi: 10.1124/jpet.117.240192. Epub 2017 Apr 25.


Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity.

Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N, Finlay D, MacDonald C, Chicca A, Gens MD, Stuart J, de Vries H, Mastrangelo N, Xia L, Alachouzos G, Baggelaar MP, Martella A, Mock ED, Deng H, Heitman LH, Connor M, Di Marzo V, Gertsch J, Lichtman AH, Maccarrone M, Pacher P, Glass M, van der Stelt M.

Nat Commun. 2017 Jan 3;8:13958. doi: 10.1038/ncomms13958.


Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.


Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Grim TW, Samano KL, Ignatowska-Jankowska B, Tao Q, Sim-Selly LJ, Selley DE, Wise LE, Poklis A, Lichtman AH.

J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):217-28. doi: 10.1515/jbcpp-2015-0118.


The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.

Wilkerson JL, Niphakis MJ, Grim TW, Mustafa MA, Abdullah RA, Poklis JL, Dewey WL, Akbarali H, Banks ML, Wise LE, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2016 Apr;357(1):145-56. doi: 10.1124/jpet.115.229971. Epub 2016 Jan 20.


Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.

Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2015 Aug;354(2):111-20. doi: 10.1124/jpet.115.222851. Epub 2015 May 21.


Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice.

Grim TW, Wiebelhaus JM, Morales AJ, Negus SS, Lichtman AH.

Drug Alcohol Depend. 2015 May 1;150:31-7. doi: 10.1016/j.drugalcdep.2015.01.022. Epub 2015 Jan 29.


Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Wiebelhaus JM, Grim TW, Owens RA, Lazenka MF, Sim-Selley LJ, Abdullah RA, Niphakis MJ, Vann RE, Cravatt BF, Wiley JL, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2015 Feb;352(2):195-207. doi: 10.1124/jpet.114.218677. Epub 2014 Nov 14.


Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models.

Grim TW, Ghosh S, Hsu KL, Cravatt BF, Kinsey SG, Lichtman AH.

Pharmacol Biochem Behav. 2014 Sep;124:405-11. doi: 10.1016/j.pbb.2014.07.008. Epub 2014 Jul 21.

Supplemental Content

Support Center